Tuberculous Lymphadenitis in a Patient Receiving PD-1 Inhibitor for Melanoma: A Case Report and Brief Literature Review

Tuberculous Lymphadenitis in a Patient Receiving PD-1 Inhibitor for Melanoma: A Case Report and Brief Literature Review

Oncolytic immunotherapy is a novel and promising approach in clinical oncology practice. Currently, immune checkpoint inhibitors (ICIs) are the first-line treatment options for disseminated melanoma. Nivolumab is a well-defined ICI that blocks programmed cell death 1 (PD-1) and mainly increases anti...

Full description

Bibliographic Details
Main Authors: Baran Akagunduz, Muhammet Ozer, Ali Cagatay Bozkina, Banu Lebe
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Current Oncology
Subjects:
tuberculous lymphadenitis
nivolumab
melanoma
immune checkpoint inhibitors
immunotheraphy
Online Access:https://www.mdpi.com/1718-7729/28/1/28

Internet

https://www.mdpi.com/1718-7729/28/1/28

Similar Items